Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 14/20 | 0.98 |
| ▸ | KDR | P35968 | 14/20 | 0.98 |
| ▸ | SRC | P12931 | 13/20 | 0.98 |
| ▸ | PDGFRB | P09619 | 13/20 | 0.98 |
| ▸ | EGFR | P00533 | 3/20 | 0.78 |
| ▸ | AURKA | O14965 | 5/20 | 0.76 |
| ▸ | FYN | P06241 | 2/20 | 0.62 |
| ▸ | YES1 | P07947 | 2/20 | 0.62 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406428 | 0.99 | FGFR1 (1.00) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6405603 | 0.99 | FGFR1 (1.00) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6695171 | 0.93 | KDR (0.84) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6701692 | 0.93 | SRC (0.84) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6698545 | 0.89 | SRC (0.79) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6696887 | 0.89 | SRC (0.79) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6692356 | 0.89 | SRC (0.78) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6696411 | 0.89 | SRC (0.78) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6696870 | 0.88 | SRC (0.77) | FGFR1KDRSRCPDGFRBEGFR | |
| SCHEMBL6394656 | 0.88 | SRC (0.80) | FGFR1KDRSRCPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | FGFR1 782/4885KDR 749/4885SRC 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.